Name | Titel | Zahlen | Ausgeübt | Geburtsjahr |
---|---|---|---|---|
Mr. Steven Saviuk CA | Chairman, President & CEO | 17,05k | N/A | 1959 |
Ms. Helen Saviuk CA | CFO & Director | 44k | N/A | N/A |
Mr. Ronald S. Perry CA, CPA | Secretary | N/A | N/A | 1956 |
Mr. Kristof Biniecki | Vice President of Scientific Affairs - Valeo Pharma Inc | 112,3k | N/A | N/A |
Mr. Marc F. Leger | Executive Vice President of Commercial Operations - Valeo Pharma Inc | 144,89k | N/A | 1959 |
Nathalie Therrien | Vice-President of QA & Regulatory Affairs - Valeo Pharma Inc. | 135,17k | N/A | N/A |
Mr. Luc Mainville M.B.A, M.B.A. | Senior VP & CFO of Valeo Pharma Inc | 135k | N/A | 1964 |
Manitex Capital Inc. focuses on acquiring interests in life sciences, cleantech, and sustainable products/technologies companies. It also holds a portfolio of marketable securities. Manitex Capital Inc. is headquartered in Kirkland, Canada.
Manitex Capital Inc.s ISS Governance QualityScore, Stand N/A, lautet N/A. Die grundlegenden Scores sind Audit: N/A, Vorstand: N/A, Shareholderrechte: N/A, Kompensation: N/A.